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Introduction
Perfluoroalkyl substances (PFAS) are 
synthetic compounds that are resistant to 
degradation and have been found world-
wide in environmental media and biota, 
including humans. The most widely studied 
PFAS are perfluorooctane sulfonate (PFOS) 
and perfluorooctanoic acid (PFOA). PFOS 
was an ingredient in the Scotchgard stain 
repellent manufactured by 3M, but the 
company decided to stop producing PFOS 
in 2002 after it had been found in wildlife 
and humans (Agency for Toxic Substances 
and Disease Registry 2009). PFOA is a 
surfactant that is used in the production of 
many consumer goods, including nonstick 
coating in cookware. The eight major 
companies producing or using PFOA have 
agreed to work toward eliminating emis-
sions and product content of PFOA by 2015 
[U.S. Environmental Protection Agency 
(EPA) 2006]. Despite the reductions in 
the production and emission of PFOS and 
PFOA, these persistent compounds can still 
be detected in biological samples from the 
general population. For example, PFOS and 
PFOA have been detected in the blood of 
> 98% of participants in the 2009–2010 U.S. 
National Health and Nutrition Examination 
Survey (NHANES) [Centers for Disease 
Control and Prevention (CDC) 2013] and 
2009–2011 Canadian Health Measure 
Survey (CHMS) (Health Canada 2013). 
PFOS and PFOA have also been detected 
in maternal blood during pregnancy, cord 
blood at delivery, and breast milk (Kim SK 
et al. 2011; Olsen et al. 2009), indicating that 
humans are exposed during critical prenatal 
and early postnatal windows of development.
Many epidemiologic studies have reported 
an association between maternal and cord 
blood PFAS levels and reductions in birth 
weight (Apelberg et al. 2007; Chen et al. 
2012; Fei et al. 2007; Maisonet et al. 2012; 
Washino et al. 2009; Whitworth et al. 2012). 
Although these studies accounted for poten-
tial confounding by many variables, none 
adjusted for glomerular filtration rate (GFR). 
GFR, the flow rate of fluid being filtrated by 
the kidneys, increases by about 50% during 
the first half of pregnancy and declines slightly 
during the second half of pregnancy (Gibson 
1973). Two studies of GFR during pregnancy 
have shown that women whose GFR fails to 
rise sufficiently during pregnancy tend to have 
smaller babies (Gibson 1973; Morken et al. 
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Background: Prenatal exposure to perfluoroalkyl substances (PFAS) has been associated with 
lower birth weight in epidemiologic studies. This association could be attributable to glomerular 
filtration rate (GFR), which is related to PFAS concentration and birth weight.
oBjectives: We used a physiologically based pharmacokinetic (PBPK) model of pregnancy to 
assess how much of the PFAS–birth weight association observed in epidemiologic studies might be 
attributable to GFR.
Methods: We modified a PBPK model to reflect the association of GFR with birth weight 
( estimated from three studies of GFR and birth weight) and used it to simulate PFAS concentra-
tions in maternal and cord plasma. The model was run 250,000 times, with variation in  parameters, 
to simulate a population. Simulated data were analyzed to evaluate the association between 
PFAS levels and birth weight due to GFR. We compared simulated estimates with those from a 
meta-analysis of epidemiologic data.
results: The reduction in birth weight for each 1-ng/mL increase in simulated cord plasma for 
perfluorooctane sulfonate (PFOS) was 2.72 g (95% CI: –3.40, –2.04), and for perfluorooctanoic 
acid (PFOA) was 7.13 g (95% CI: –8.46, –5.80); results based on maternal plasma at term were 
similar. Results were sensitive to variations in PFAS level distributions and the strength of the 
GFR–birth weight association. In comparison, our meta-analysis of epidemiologic studies suggested 
that each 1-ng/mL increase in prenatal PFOS and PFOA levels was associated with 5.00 g (95% CI: 
–21.66, –7.78) and 14.72 g (95% CI: –8.92, –1.09) reductions in birth weight, respectively.
conclusion: Results of our simulations suggest that a substantial proportion of the association 
between prenatal PFAS and birth weight may be attributable to confounding by GFR and that 
confounding by GFR may be more important in studies with sample collection later in pregnancy.
citation: Verner MA, Loccisano AE, Morken NH, Yoon M, Wu H, McDougall R, Maisonet M, 
Marcus M, Kishi R, Miyashita C, Chen MH, Hsieh WS, Andersen ME, Clewell HJ III, 
Longnecker MP. 2015. Associations of perfluoroalkyl substances (PFAS) with lower birth weight: 
an evaluation of potential confounding by glomerular filtration rate using a physiologically 
based pharmacokinetic model (PBPK). Environ Health Perspect 123:1317–1324; http://dx.doi.
org/10.1289/ehp.1408837
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2014). On the other hand, GFR is likely to 
influence the urinary excretion of xenobiotics 
like PFAS. Indeed, higher blood PFAS levels 
have been observed in people with lower GFR 
(Shankar et al. 2011; Watkins et al. 2013). 
Watkins et al. (2013) evaluated the direc-
tion of the association between PFOA and 
reduced kidney function (indicated by GFR) 
by comparing results obtained with measured 
serum PFOA levels (which could be influ-
enced by GFR) and estimated serum PFOA 
levels (which were independent of GFR): An 
association was observed only with measured 
PFOA, suggesting that the association may 
be a consequence of, rather than a cause of, 
decreased kidney function. If so, women with 
lower GFR during pregnancy would tend to 
have smaller babies and higher blood PFAS 
levels. This raises the possibility that GFR 
confounds the association between prenatal 
PFAS exposure and birth weight. To what 
extent GFR influences this association has yet 
to be evaluated.
In this study, we assessed how much 
of the epidemiologic association between 
prenatal PFOS and PFOA (PFAS thereafter) 
exposure and birth weight could be attribut-
able to confounding by GFR. We modified 
a recently developed physiologically based 
pharmacokinetic (PBPK) model of PFAS 
during pregnancy (Loccisano et al. 2013) 
to reflect the association between GFR and 
PFAS levels and birth weight. The model was 
run repeatedly, using Monte Carlo simula-
tion techniques, with variation in parameters, 
to simulate a population. Estimates of the 
birth weight–PFAS association obtained 
from simulated PFAS levels and birth 
weight were subsequently compared with 
estimates from a meta-analysis of existing 
 epidemiologic studies.
Methods
Overview. We used a PBPK model to run 
Monte Carlo simulations of a study popula-
tion and to generate pairs of predictions for 
PFAS level and birth weight. PBPK-derived 
estimates were subsequently analyzed by 
linear regression. We also performed a meta-
analysis of published epidemiologic studies 
of prenatal PFAS exposure and birth weight 
to obtain summary effect estimates. Results 
obtained from simulated PFAS levels and 
birth weights were compared with results 
from our meta-analysis to evaluate how much 
of this association might be attributable to the 
influence of GFR.
The PBPK model .  We modified a 
published PBPK model of PFOA and PFOS 
during pregnancy (Loccisano et al. 2013). 
This multi-compartment model included 
maternal compartments (plasma, liver, fat, 
gut, skin, mammary, rest of body, kidney, 
filtrate, and storage) and the placenta, fetal 
plasma, rest of fetal body, and amniotic fluid 
(Figure 1). Exposure to PFAS was modeled as 
an input into the maternal plasma compart-
ment to encompass absorbed doses through 
different routes. Distribution in the different 
compartments was driven by blood flow rates 
in and out of compartments, tissue volume, 
and tissue:blood partition coefficients. PFAS 
excretion in urine was modeled as a multi-
step process: The free (unbound) PFAS in 
plasma was first filtered through the kidneys 
followed by extensive active reabsorption, 
with the unreabsorbed fraction continuing its 
way to a storage compartment before excre-
tion. We updated the description of placental 
blood flow and fetal cardiac output according 
to equations presented by Yoon et al. (2011). 
The modified version of the PBPK model 
code is provided in Supplemental Material, 
“PBPK Model Code.” A conceptual repre-
sentation with basic mass-balance differential 
equations is also provided in Supplemental 
Material, Figure S1.
We also modified the model so that the 
initial body burden (at the beginning of preg-
nancy) and intake rate during pregnancy are 
calculated based on an initial plasma PFAS 
level [Cinitial (nanograms per milliliter)]. 
The initial amount of PFAS in the different 
maternal tissues (Amountt) at each Monte 
Carlo simulation (i) was computed as the 
product of the initial plasma PFAS level 
(Cinitial), the tissue:plasma partition coefficient 
(Partitiont) and the tissue volume (Volumet):
Amountt(i) = Cinitial(i) × Partitiont(i)  
 × Volumet(i). [1]
Maternal PFAS intake rate during pregnancy 
was estimated from initial plasma PFAS 
level. To estimate maternal PFAS intake rate 
during pregnancy, we assumed the initial 
plasma PFAS level to be at steady state. The 
hourly intake rate was calculated accordingly 
using a rearrangement of a classic steady state 
equation that accounts for compound-specific 
half-life (hours), volume of distribution 
(liters), and dosing interval (hours) (Dhillon 
and Kostrzewski 2006):
Intake (ng/hr)(i) = Cinitial(i)  
 × Volume of distribution(i)  
 × Dosing interval  
 × ln(2)/Half-life, [2]
where the volume of distribution was calcu-
lated based on partition coefficients and organ 
volumes, the dosing interval was 1 hr (simula-
tion time increment), and the half-lives of 
PFOS and PFOA were 47,304 hr (5.4 years) 
and 33,288 hr (3.8 years) (Olsen et al. 2007).
To parameterize the relationship between 
GFR and birth weight, we performed a meta-
analysis of three studies where individual-
specific paired GFR and birth weight 
measurements were available in the publica-
tion or made available to us (Dunlop 1981; 
Gibson 1973; Morken et al. 2014). Other 
studies of GFR or indicators of GFR (e.g., 
serum creatinine, serum uric acid) and birth 
weight were identified but did not report 
individual-specific data or regression coef-
ficients and, consequently, could not be used 
in our meta-analysis (Akahori et al. 2012; 
Davison and Hytten 1974; Dunlop et al. 
Figure 1. Structure of human gestation PBPK model for PFOS and PFOA adapted from Loccisano et al. 
(2013) with permission of Taylor & Francis LLC. 
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1978; Duvekot et al. 1995; Knopp et al. 
1985; Laughon et al. 2009). Because GFR 
changes during pregnancy and the measure-
ments were taken at different times during 
pregnancy, we calculated standardized GFR 
values (GFRratio) as the ratio of the observed 
GFR for each subject to the mean GFR at 
that gestational age [Gibson 1973 (28 gesta-
tional weeks); Dunlop 1981 (26 gestational 
weeks); Morken et al. 2014 (mean, 18 gesta-
tional weeks)]. We computed the coefficient 
relating birth weight to GFRratio as the inverse 
variance–weighted average of the coefficient 
based on regression models of data from 
Gibson (1973) (n = 20), Dunlop (1981) 
(n = 25), and Morken et al. (2014) (n = 953). 
The raw data from these studies were either 
presented in the original publication (Gibson 
1973; Dunlop 1981) or were available to us 
(Morken et al. 2014). In the first two studies, 
GFR was measured using inulin clearance. In 
the third study, GFR was estimated based on 
plasma creatinine and the Cockroft–Gault 
formula (Koetje et al. 2011). A separate 
multiple regression model of birth weight was 
fitted for each study; all models were adjusted 
for gestational age at birth. The Morken et al. 
(2014) data were additionally adjusted for 
prepregnancy body weight and sampling 
strata. Because estimation of GFR on the 
basis of a single measure of plasma creati-
nine is known to be imprecise (Aras et al. 
2012), the coefficient for GFRratio from the 
Morken et al. (2014) study was deattenuated 
to account for the effect of measurement error 
(Willett 1990), by dividing by an intraclass 
correlation coefficient of 0.76 for serum creat-
inine (Al-Delaimy et al. 2006) before calcu-
lating the overall inverse-variance weighted 
average. Each unit increase in GFRratio was 
associated with an increase in birth weight 
(± SE) of 67 ± 535 g in the Dunlop (1981) 
study, 1,603 ± 784 g in the Gibson (1973) 
study, and 164 ± 77 g in the Morken et al. 
(2014) study. The meta-analytic coefficient 
was a 175.5 ± 75.9-g increase in birth weight 
per unit increase in GFRratio.
We used a two-tier approach to generate 
variability in GFRratio and induce an asso-
ciation between GFRratio and birth weight 
in Monte Carlo simulations. For each 
Monte Carlo simulation (i), we first sampled 
a GFRratio value from the distribution of 
GFRratio in the data of Morken et al. (2014) 
[mean ± SD, 1.0 ± 0.246; range, 0.508–1.492 
(± 2 SDs)]. The SD from Morken et al. 
(2014) was selected because in this more 
recent study, the distribution of GFRratio 
was considered to be more relevant because 
of the increase in prevalence of overweight 
and obesity and the correlation of GFR with 
body mass index (Bosma et al. 2004). During 
each simulation, the time-course of GFR 
(GFRt) during pregnancy was obtained by 
multiplying the reference gestational GFRt 
profile (GFR as a function of time elapsed 
since conception, as described in the original 
PBPK model) by the sampled GFRratio:
GFRt(i) = GFRratio(i)  
 × Reference gestational GFRt. [3]
Then we calculated a birth weight according 
to the meta-analytic regression between 
GFRratio and birth weight derived from three 
studies, as described above. This was accom-
plished by using the equation derived from 
the aforementioned regression and randomly 
sampling an error term based on the distribu-
tion of residuals:
Calculated birth weight (g)(i)  
 = Intercept + β × GFRratio(i)  
  + Residual(i), [4]
where the intercept was 3,376 g, the β was 
175.5 g per 1-unit increase in GFRratio, and 
the residual was sampled from a distribu-
tion with a mean of 0 g, an SD of 441 g, 
and ranging from –882 g to 882 g (± 2 SDs). 
Fetal growth in the original PBPK model 
was described using a time-dependent fetal 
growth curve (Loccisano et al. 2013). We 
adjusted this standard fetal growth curve 
to match the calculated birth weight from 
Equation 4. To do so, we multiplied the 
standard fetal growth curve (reference fetal 
weightt) by the ratio of calculated birth 
weight on the reference fetal weightt at 
delivery (3,509 g). For each simulation (i), 
the time-course of fetal weight (fetal weightt) 
was described using the following equation:
Fetal weightt(i)  
 = (Calculated birth weight(i)/3,509 g)  
  × Reference fetal weightt.  [5]
PBPK model global sensitivity analysis. 
Because the PBPK model used herein incor-
porates > 40 parameters that can vary within a 
population (e.g., volume of organs, perfusion 
rates, tissue:plasma partition coefficients), 
we first ran a sensitivity analysis to identify 
parameters with the highest relative influ-
ence on maternal plasma PFAS levels across 
pregnancy and cord plasma PFAS levels at 
delivery. We opted for the Morris global 
method, which evaluates parameter sensi-
tivity over a range of physiological scenarios 
by taking the mean of many local sensitivity 
analyses calculated over the entire param-
eter space, thus accounting for interactions 
(McNally et al. 2011). We allowed param-
eters to vary between 70% and 130% of their 
mean value—a 15% coefficient of variation 
with bounds at ± 2 SDs. For this exercise, 
we used initial maternal plasma levels of 
13.02 ng/mL for PFOS and 2.53 ng/mL for 
PFOA to reflect levels in published epidemio-
logic studies as noted below in the “Monte 
Carlo simulations” section. Sensitivity coef-
ficients were calculated by adapting the M 
code of the Morris Test included in the acslX 
Optimum suite of tools (Aegis Technologies 
Inc., Huntsville, AL, USA) to our study. The 
set of most influential parameters—those 
for which small perturbations have the most 
significant effect on PFOS and PFOA levels 
(coefficient within a factor of 10 of the most 
sensitive model parameter at any month of 
pregnancy or at delivery)—were allowed to 
vary in the Monte Carlo analyses.
Assessment of PBPK model accuracy. To 
assess how well the model describes the phar-
macokinetics of PFAS during pregnancy, we 
compared simulated plasma PFAS profiles 
with observed serial levels. We identified 
two reports with data that were not used by 
Loccisano et al. (2013) for model develop-
ment and met the following criteria: presented 
two serial maternal blood PFAS levels, and 
presented sufficient information on sample 
collection times (Glynn et al. 2012; Monroy 
et al. 2008). For each of the two reports 
and each PFAS (PFOS and PFOA), we 
performed 10,000 Monte Carlo iterations. 
At each Monte Carlo iteration, the model 
a) sampled values for sensitive parameters 
identified in the global sensitivity (Table 1); 
b) sampled a plasma PFAS level from the 
published distributions at the first blood 
sample collection time point; c) adjusted the 
initial plasma level (at the time of concep-
tion), by iterative model simulations, to obtain 
matching simulated and sampled PFAS level 
at the time of the first blood sample collec-
tion (tolerance: 0.1%); and d) simulated a 
complete pharmacokinetic profile based on 
the initial plasma level. We visually compared 
the distribution of simulated plasma PFAS 
profiles from the Monte Carlo iterations with 
the distribution of observed PFAS levels in the 
second blood samples from the two reports 
mentioned above.
Monte Carlo simulation. We used a 
Monte Carlo procedure to simulate popula-
tion PFOA and PFOS levels across pregnancy. 
At each Monte Carlo iteration, the PBPK 
model sampled values for sensitive parameters 
identified in the global sensitivity analyses and 
initial blood PFAS levels from probabilistic 
distributions (Table 1) before simulation of 
PFAS levels during the 9 months of pregnancy. 
To be able to compare results from simula-
tions with those from epidemiologic studies 
on PFAS and birth weight included in our 
meta-analysis [described below in “Meta-
analysis of PFAS-birth weight epidemiologic 
studies” (Apelberg et al. 2007; Chen et al. 
2012; Fei et al. 2007; Hamm et al. 2010; 
Maisonet et al. 2012; Washino et al. 2009; 
Whitworth et al. 2012)], we used initial plasma 
Verner et al.
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PFAS distributions based on levels reported in 
these studies. We calculated the mean PFOS 
(13.02 ng/mL) and PFOA (2.53 ng/mL) levels 
by averaging the reported mean or median 
maternal blood or cord blood levels (studies 
were weighted equally). These epidemiologic 
studies reported different measures of spread 
for blood PFAS levels (i.e., range, standard 
deviation, geometric standard deviation, 
interquartile range). Because these measures 
of spread cannot be directly combined, we 
derived a standard deviation based on coef-
ficients of variations of 0.37 for PFOS and 
0.45 for PFOA calculated using data from 
Fei et al. (2007), the largest study (n = 1,399) 
included in our meta-analysis (described 
below). Monthly simulated maternal plasma 
PFAS levels, simulated cord plasma levels at 
delivery, and calculated birth weight were 
collected from simulations to be used in regres-
sion models of PFAS and birth weight. We 
ran 250,000 Monte Carlo iterations to achieve 
convergence in the PFAS–birth weight linear 
regression coefficient (β).
Sensitivity analyses. We evaluated the 
influence of different assumptions on the asso-
ciation between PBPK-derived PFAS levels 
and birth weight. In addition to analyses 
noted above, we ran multiple Monte Carlo 
simulations with different parameters for 
PFAS distributions (higher and lower means 
and standard deviations) and different coef-
ficients for the GFR–birth weight association. 
Specifically, we halved or doubled these three 
parameters, one at a time. We also ran Monte 
Carlo simulations with different sampling 
seeds to evaluate reproducibility. We identi-
fied two studies that evaluated PFOA half-
life in populations exposed through drinking 
water; Brede et al. (2010) estimated a half-life 
of 3.26 years, which is similar to the 3.8-year 
half-life used in our study (Olsen et al. 2007), 
whereas Bartell et al. (2010) estimated a 
shorter half-life of 2.3 years. To evaluate the 
impact of a shorter half-life on our results, 
additional Monte Carlo simulations were 
carried out using the half-life reported by 
Bartell et al. (2010).
Meta-analysis of PFAS–birth weight epide-
miologic studies. We identified human studies 
published in English in 2012 or earlier using 
the PubMed (http://www.ncbi.nlm.nih.gov/
pubmed) search terms “birth weight” and 
“perfluorooctane sulfonate” or “perfluoro-
octanoic acid.” This identified articles with the 
search terms in the title, abstract, or key words. 
To be eligible for inclusion in the analysis, 
the study had to have results available from 
a multiple regression model of birth weight 
(grams) as a function of PFOS or PFOA 
in nanograms per milliliter concentration in 
maternal blood from pregnancy or cord blood. 
In one case (Apelberg et al. 2007), the β coef-
ficient originally published (grams birth weight 
per interquartile increase in PFAS) was reex-
pressed as nanograms per milliliter by using 
the interquartile distance. In three instances 
we found studies that had fit models similar 
to what we sought, but the published results 
could not be reexpressed to obtain a reason-
able approximation of what we needed. In 
these cases we contacted the original authors to 
obtain the coefficients of interest. Specifically, 
Washino et al. (2009) and Chen et al. (2012) 
had fit models with log of PFAS as the inde-
pendent exposure variable, and Maisonet et al. 
(2012) had fit the desired model but had not 
put the β coefficients in the publication. We 
used these regression coefficients to calculate 
inverse variance–weighted summary β coeffi-
cients for PFOS and PFOA. A list of included 
and excluded studies and a brief descrip-
tion of each is provided in Supplemental 
Material, Table S1.
Results
PBPK modeling of PFAS levels. We first 
performed a Morris global sensitivity analysis 
to identify sensitive model parameters, where 
a higher coefficient means greater sensitivity. 
The following parameters had a sensitivity 
coefficient within a factor of 10 of the most 
sensitive parameter at some point during 
pregnancy or at delivery: prepregnancy body 
weight, liver volume, liver:plasma partition 
coefficient, rest of body:plasma partition coef-
ficient, free fraction in maternal and cord 
plasma, renal reabsorption constant, and 
maximum reabsorption velocity (sensitivity 
coefficients are presented in Supplemental 
Material, Table S2). For example, the most 
sensitive parameter for PFOS levels in cord 
plasma was the free fraction in fetal plasma 
(global sensitivity coefficient = 0.0046). In 
a one-at-a-time sensitivity analysis, a 10% 
change in this parameter was associated with 
an 8.9% change in simulated cord plasma 
PFOS level. In comparison, a 10% change 
in the liver volume (global sensitivity coef-
ficient = 0.0003) was associated with a 0.9% 
change in simulated cord plasma PFOS level.
To assess model accuracy, we simulated 
maternal plasma PFAS levels based on the first 
of the two serial measurements of PFAS from 
two published studies (Glynn et al. 2012; 
Monroy et al. 2008) and visually compared 
simulated profiles with observed levels 
(Figure 2). Simulated and observed PFOS 
and PFOA levels declined over the course of 
pregnancy in a similar fashion. However, the 
model slightly underestimated the decline in 
PFOA levels from the Glynn et al. (2012) 
study: Mean simulated PFOA level at the time 
of second blood draw was 4.3 ng/mL, whereas 
mean reported level was 4.0 ng/mL.
In linear regression analyses, the asso-
ciation between simulated maternal and cord 
plasma PFAS levels and birth weight was 
dependent on the time elapsed after concep-
tion. For both PFOA (Figure 3A) and PFOS 
(Figure 3B), the association between simulated 
maternal plasma levels and birth weight only 
appeared after the third month of pregnancy 
and was strongest at the time of delivery. The 
association between simulated PFOA levels 
and birth weight was similar for maternal 
plasma at term [β: –7.9 g; 95% confidence 
interval (CI): –9.4, –6.4] and cord plasma (β: 
–7.1 g; 95% CI: –8.5, –5.8). For PFOS, the 
association between simulated cord plasma 
levels and birth weight (β: –2.7 g; 95% CI: 
–3.4, –2.0) was slightly stronger than that esti-
mated based on simulated maternal plasma 
levels (β: –1.5 g; 95% CI: –1.8, –1.1).
Table 1. Distributions of parameters used in the Monte Carlo simulations.
Parameter PFAS Mean ± SD Minimum Maximum
Standardized glomerular filtration rate (GFRratio)a — 1.000 ± 0.246 0.508 1.492
Residual birth weight (g)b — 0 ± 441 –882 882
Prepregnancy body weight (kg)c — 70.3 ± 14.3 37.0 134.0
Volume of liver as a fraction of body weightd — 0.026 ± 0.004 0.018 0.034
Liver:plasma partition coefficientd PFOS 3.720 ± 0.558 2.604 4.836
PFOA 2.200 ± 0.330 1.540 2.860
Rest of body:plasma partition coefficientd PFOS 0.200 ± 0.030 0.140 0.260
PFOA 0.120 ± 0.018 0.084 0.156
Free fraction in maternal plasmad PFOS 0.025 ± 0.004 0.017 0.033
PFOA 0.020 ± 0.003 0.014 0.026
Free fraction in fetal plasmad PFOS 0.025 ± 0.004 0.017 0.033
PFOA 0.020 ± 0.003 0.014 0.026
Resorption maximum velocity (mg/hr/kg0.75)d PFOS 3.500 ± 0.525 2.450 4.550
PFOA 10.00 ± 1.50 7.000 13.000
Affinity constant (mg/L)d PFOS 0.023 ± 0.003 0.017 0.029
PFOA 0.055 ± 0.008 0.039 0.071
Initial plasma PFAS levels (ng/mL) PFOS 13.02 ± 4.79 0.01 100.00
PFOA 2.53 ± 1.13 0.01 100.00
All distributions were assumed to be normal. Values presented are arithmetic means and SDs.
aDistribution of GFRratio pooled from the three selected studies (Dunlop 1981; Gibson 1973; Morken et al. 2014). bFrom the 
GFRratio–birth weight meta-analytic regression. cDistribution of prepregnancy body weight from the Norwegian Mother 
and Child Cohort Study (MoBa). dMean values taken from Loccisano et al. (2013); SDs were calculated assuming a 
 coefficient of variation of 15%, and bounds were set to ± 2 SD. 
Glomerular filtration rate, PFAS, and birth weight
Environmental Health Perspectives • volume 123 | number 12 | December 2015 1321
In sensitivity analyses, we evaluated 
whether the results were robust to changes 
in initial plasma PFAS level distributions 
(mean and SD), variations in coefficients 
for the GFR–birth weight association and 
different Monte Carlo sampling seeds (repro-
ducibility). These analyses showed that the 
strength of the simulated PFAS–birth weight 
association (i.e., confounding by GFR) is 
influenced by initial plasma PFAS level 
distributions and the GFR–birth weight coef-
ficient: Stronger associations were obtained 
with lower mean initial plasma PFAS levels 
and lower SDs, and with higher GFR–birth 
weight coefficients (Table 2). When more 
than one parameter was changed at a time, 
their influence was additive. As an example, 
a lower PFOA mean (multiplier = 0.5) and 
a stronger β for the GFR–birth weight asso-
ciation (multiplier = 2) resulted in a 23.3-g 
(95% CI: –26.0, –20.6) decrease in birth 
weight per nanograms per milliliter increase 
in simulated cord plasma levels; conversely, 
a higher PFOA mean (multiplier = 2) and 
a weaker β for the GFR–birth weight asso-
ciation (multiplier = 0.5) resulted in a 2.4-g 
(95% CI: –3.1, –1.8) decrease in birth weight 
per nanograms per milliliter increase in 
simulated cord plasma levels. Results from 
Monte Carlo simulations using different 
sampling seeds did not vary substantially, 
which supports the reproducibility of 
results (Table 2). Using a shorter half-life 
of 2.3 years for PFOA (compared with 3.8 
in main analyses) increased the strength of 
the association between simulated levels in 
maternal plasma at term and birth weight 
by 21% (β: –9.6 g; 95% CI: –11.0, –8.2) 
and between simulated levels in cord 
plasma and birth weight by 14% (β: –8.1 g; 
95% CI: –9.4, –6.8).
Meta-analysis of epidemiologic studies. 
All studies of prenatal PFOA reported an 
association with reduced birth weight, 
with β coefficients ranging from –2.1 g to 
–64.4 g per nanograms per milliliter increase 
in PFOA levels (Figure 3A). An association 
Figure 2. Comparison of simulated versus measured levels from Glynn et al. (2012) and Monroy et al. (2008). 
Distributions of simulated levels are from 10,000 Monte Carlo simulations.
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between PFOS and reduced birth weight 
was observed in six of seven studies, with β 
coefficients ranging from –13.0 g to –0.5 g 
per nanograms per milliliter increase in 
PFOS levels (Figure 3B). The summary 
β  coefficients for grams birth weight 
per nanograms per milliliter increase in 
PFOA and PFOS levels were –14.7 g 
(95% CI: –21.7, –7.8) and –5.0 g (95% CI: 
–8.9, –1.1), respectively.
Discussion
In this study, we aimed to evaluate how much 
of the epidemiologic association between 
prenatal exposure to PFAS and reduced birth 
weight might be attributable to confounding 
by GFR. Results from Monte Carlo PBPK 
model simulations suggest that GFR drives a 
portion of this association, but not all of it, 
and that its influence becomes more impor-
tant with increasing gestational weeks.
When our default assumptions were 
applied, the association between simulated 
maternal and cord plasma PFAS levels at the 
time of delivery and birth weight represented 
a substantial proportion of the association 
observed in our meta-analysis of epidemio-
logic studies. This suggests that epidemio-
logic studies presented herein, which have not 
controlled for GFR, might have overesti-
mated the influence of prenatal exposure 
to PFAS on fetal growth. Our results also 
suggested that GFR had less influence on 
PFAS levels in maternal plasma early in 
pregnancy. In a meta-regression analysis 
of the epidemiologic data in Figure 3 that 
we conducted (not shown), week of blood 
draw was associated with a larger negative 
coefficient for PFOS (–0.39 g birth weight 
per nanograms per milliliter increase in PFOS 
per gestational week, p < 0.01). For PFOA, 
the corresponding coefficient was –0.006, 
p = 0.98. Although the meta-regression results 
support our hypothesis for PFOS, the lack 
of support for PFOA could be attributable 
to the small number of studies included, and 
other sources of heterogeneity.
In light of these results, epidemiologic 
studies investigating the effects of prenatal 
PFAS on fetal growth should account for 
the influence of GFR. Different approaches 
could be considered. An option would be to 
sample maternal plasma before pregnancy 
or during the first trimester, when changes 
in GFR have not yet influenced PFAS 
significantly according to simulated results. 
Statistically adjusting for GFR estimated 
from plasma creatinine levels or cystatin C 
levels (Tidman et al. 2008) could also help 
reduce confounding by GFR. Another 
approach would be to use a PBPK model to 
simulate results that are specific to their study 
sample collection time and PFAS distribu-
tion. Assuming the PBPK model and key 
assumptions are valid, the contribution of 
GFR to the observed association could be 
inferred from a comparison of simulated 
versus observed results. Two studies of 
communities with high exposure to PFOA 
have used PFOA serum levels estimated using 
one-compartment pharmacokinetic model 
coupled with a model for individual exposure 
to evaluate the association between prenatal 
exposure and birth outcomes (Savitz et al. 
2012a, 2012b). Because the PFOA level esti-
mates were not based on biological levels, the 
association between estimated levels and birth 
outcomes cannot be confounded by GFR. 
Of note, these studies were not suggestive 
of an association between prenatal PFOA 
exposure and birth weight (Savitz et al. 
2012b). For example, in Savitz et al. (2012b), 
based on data for 4,534 births, the adjusted 
change in birth weight per 100-ng/mL 
increase in estimated serum PFOA was –15 g 
(95% CI: –43, 14).
Our results also have implications with 
regard to future meta-analyses of prenatal 
PFAS and birth weight. As noted by Egger 
et al. (1998), the real strength of meta-
analyses is to identify factors responsible for 
heterogeneity across studies. According to 
our simulations, the contribution of GFR 
to the association between simulated PFAS 
levels and birth weight is influenced by the 
timing of sample collection and PFAS level 
distribution (mean and SD). A meta-analysis, 
including a meta-regression, based on more 
studies, and consideration of other sources of 
heterogeneity, would be of interest.
Certain assumptions might have intro-
duced bias in our study. Because individual-
specific data on GFR, PFAS, and birth weight 
were not available, we could evaluate the 
PBPK model validity only on a population 
level. Should extensive individual-specific 
measurements be available during pregnancy, 
the model could be further calibrated and 
evaluated. Nevertheless, when we simu-
lated plasma PFAS levels across pregnancy 
in women from two studies who had their 
blood levels measured twice, simulated 
levels followed a decline in PFAS levels that 
closely matched reported levels. Because the 
Table 2. Sensitivity analyses evaluating the influence of the PFAS distribution and the strength of the GFR–birth weight association on the simulated change in 
birth weight (g) per ng/mL increase in PFAS levels attributable to GFR.
Multiplier
Sampling seed
Change in birth weight (g) per ng/mL increase in
Mean PFAS levela
Coefficient of variation 
PFAS levelsb
Beta of the GFR–birth 
weight associationc
Maternal plasma PFAS level at delivery 
[β (95% CI)]
Cord plasma PFAS level at delivery 
[β (95% CI)]
PFOA     
1 (main results) 1 (main results) 1 (main results) 123456789 –7.92 (–9.42, –6.43) –7.13 (–8.46, –5.80)
2 1 1 123456789 –3.96 (–4.70, –3.21) –3.56 (–4.23, –2.90)
0.5 1 1 123456789 –15.88 (–18.86, –12.89) –14.28 (–16.95, –11.62)
1 2 1 123456789 –3.29 (–4.19, –2.40) –3.20 (–4.03, –2.37)
1 0.5 1 123456789 –26.07 (–28.75, –23.39) –17.59 (–19.67, –15.51)
1 1 2 123456789 –13.40 (–16.80, –14.92) –11.66 (–13.01, –10.31)
1 1 0.5 123456789 –5.17 (–6.66, –3.68) –4.86 (–6.18, –3.53)
1 1 1 11111 –8.51 (–10.01, –7.02) –7.33 (–8.67, –5.99)
1 1 1 99999 –7.77 (–9.27, –6.28) –6.89 (–8.23, –5.56)
PFOS     
1 (main results) 1 (main results) 1 (main results) 123456789 –1.46 (–1.81, –1.11) –2.72 (–3.40, –2.04)
2 1 1 123456789 –0.73 (–0.91, –0.56) –1.36 (–1.70, –1.02)
0.5 1 1 123456789 –2.93 (–3.63, –2.23) –5.45 (–6.81, –4.09)
1 2 1 123456789 –0.54 (–0.75, –0.34) –1.15 (–1.57, 0.73)
1 0.5 1 123456789 –5.16 (–5.80, –4.51) –6.60 (–7.65, –5.55)
1 1 2 123456789 –2.77 (–3.12, –2.41) –5.01 (–5.70, –4.32)
1 1 0.5 123456789 –0.81 (–1.16, –0.46) –1.57 (–2.25, –0.90)
1 1 1 11111 –1.80 (–2.15, –1.44) –3.13 (–3.82, –2.45)
1 1 1 99999 –1.42 (–1.77, –1.07) –2.68 (–3.36, –2.00)
aMean values were 2.53 ng/mL for PFOA and 13.02 ng/mL for PFOS in main analyses. bCoefficients of variation were 0.446 for PFOA and 0.368 for PFOS in main analyses. cThe beta in of 
the GFR–birth weight association was 175.5 g per 1-unit increase GFRratio in the main analyses.
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simulated association between PFAS and 
birth weight was shown to be sensitive to 
the distribution of PFAS levels, the strength 
of the association between simulated PFAS 
levels and birth weight from this study cannot 
be compared with epidemiologic studies or 
meta-analyses with a different distribution 
of plasma PFAS levels. The coefficient of the 
GFR–birth weight association used in the 
Monte Carlo simulation was also shown to 
be a sensitive parameter. Should the true asso-
ciation between GFR and birth weight be 
stronger or weaker than the meta-analytic 
relation used in this study, one would expect 
the simulated association between PFAS and 
birth weight to change accordingly (i.e., a 
stronger GFR–birth weight association would 
increase the strength of the simulated PFAS–
birth weight association and vice versa). 
We also did not account for the potential 
association between GFR and initial PFAS 
concentration at conception. For example, 
prepregnancy GFR was correlated with GFR 
during pregnancy in the Gibson (1973) study 
(r = 0.55–0.69) and in the Dunlop (1981) 
study (r = 0.27–0.30), although correla-
tions were statistically significant only in the 
Gibson (1973) study. If prepregnancy GFR 
is associated with GFR during pregnancy, 
we could have underestimated the portion 
of the PFAS–birth weight association that 
is attributable to GFR by not accounting 
for the relationship between GFR and 
initial PFAS level. Also, we did not account 
for correlations across model parameters in 
Monte Carlo simulations, a factor that may 
have increased the spread of simulated blood 
PFAS levels (Burmaster and Anderson 1994). 
The assumptions that the initial plasma PFAS 
level is at steady state and that PFAS intake 
on a body weight basis is constant throughout 
pregnancy may oversimplify variations that 
are expected to occur in reality.
The meta-analysis for PFOA that we 
did was based on data for > 4,000 subjects. 
The more formal meta-analysis by Johnson 
et al. (2014) included two additional studies, 
each with < 50 subjects (Fromme et al. 
2010; Kim S et al. 2011). In addition, the 
value we used to represent the data from the 
Washino et al. (2009) study was adjusted 
for more factors than was the one used by 
Johnson et al. (2014), and the value we used 
was closer to the null. Thus, the slightly 
more negative summary in Johnson et al. 
(2014) (–18.9 g/ng/mL) than in our study 
(–14.7 g/ng/mL) was probably attributable 
to the inclusion of the two additional studies 
and the different coefficient for the Washino 
et al. (2009) result. We regard the two meta-
analyses as showing close agreement.
In a recent systematic review of the 
literature, Lam et al. (2014) concluded that 
there was sufficient evidence of an association 
between prenatal PFOA and fetal growth. 
Authors evaluated the hypothesis that GFR 
influences the PFOA–fetal growth association 
by reviewing the literature on GFR and fetal 
growth. They suggested that there is insuf-
ficient evidence for an association between 
maternal GFR during pregnancy and fetal 
growth, and they consequently rejected the 
hypothesis that GFR underlies the relationship 
between PFOA and fetal growth. However, 
Lam et al. (2014) did not include the study by 
Morken et al. (2014) in their systematic review 
of GFR and fetal growth, most likely because 
the results had not been published at the time. 
This new study by Morken et al. (2014), by 
far the largest to date (n = 953), revealed a 
significant association between estimated 
GFR and birth weight. When considering 
all available studies on the subject, we found 
that large studies consistently demonstrated an 
association between estimated GFR or indi-
cators of GFR (e.g., serum creatinine, serum 
uric acid) and birth weight [Akahori et al. 
2012 (n = 120); Knopp et al. 1985 (n = 272); 
Laughon et al. 2009 (n = 212); Morken et al. 
2014 (n = 953)], whereas results from smaller 
studies have been inconsistent [Davison and 
Hytten 1974 (n = 10); Dunlop 1981 (n = 25); 
Dunlop et al. 1978 (n = 34); Duvekot et al. 
1995 (n = 16); Gibson 1973 (n = 21)]. Given 
the new evidence, there is reason to believe a 
true association exists between maternal GFR 
during pregnancy and birth weight. Yet our 
results, which are based on the association 
between GFR and birth weight from three 
studies with  individual- specific paired GFR 
and birth weight measurements (Dunlop 
1981; Gibson 1973; Morken et al. 2014), are 
not in contrast with the conclusion of Lam 
et al. (2014). Rather than suggesting that GFR 
is the sole driver of the association between 
prenatal PFAS and birth weight, our results 
indicate that a portion of the association may 
be attributable to confounding by GFR, and 
that effect estimates may be overpredicted 
in epidemiologic studies where GFR is not 
accounted for.
Conclusion
Results from our simulations suggest that 
epidemiologic studies of prenatal PFAS 
and birth weight may have overestimated 
the strength of the association. This study 
adds to existing studies demonstrating that 
pharmaco kinetic models can be used to 
provide insight into the direction (Watkins 
et al. 2013) and the strength of epidemio-
logic associations (Verner et al. 2013). By 
combining results from epidemiologic studies 
with pharmacokinetic analyses, researchers 
will be able to identify underlying factors that 
can positively or negatively confound asso-
ciations and to estimate their contribution to 
observed effect estimates.
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